Tobira Therapeutics Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Tobira Therapeutics is a biotechnology company focused on developing therapeutics to address liver disease, HIV-1, fibrosis, and inflammation. Its lead candidate cenicriviroc (CVC) is an immunomodulator being explored for multiple indications, including non-alcoholic steatohepatitis (NASH) and kidney fibrosis, as well as HIV-1 and other conditions. The company, based in South San Francisco, California, is a small organization whose leadership has broad experience in advancing therapies for liver disease and HIV-1. 

The primary target is NASH, with a Phase 2 trial planned for the second half of 2014. In HIV-1 infection, CVC is described as Phase 3-ready, with potential as the backbone in a fixed-dose combination therapy. Across completed Phase 1 and 2 trials, CVC has a safety and tolerability profile established in about 550 subjects, including 115 HIV-1-infected participants treated for up to 48 weeks.

Get verified Tobira Therapeutics emails free

Company overview Employee directory